Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Section Content Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail
-

Sprycel (dasatinib) tablets

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) 

 

October 2011

Summary View

 

ADVERSE REACTIONS

Postmarketing Experience
  • pulmonary arterial hypertension

 

October 2010

Summary View

 

WARNINGS and PRECAUTIONS

Congestive Heart Failure, Left Ventricular Dysfunction, and Myocardial Infarction
  • Cardiac adverse reactions were reported in 5.8% of 258 patients taking Sprycel, including 1.6% of patients with cardiomyopathy, heart failure congestive, diastolic dysfunction, fatal myocardial infarction, and left ventricular dysfunction. Monitor patients for signs or symptoms consistent with cardiac dysfunction and treat appropriately.

 

July 2010

Summary View

 

Dose Adjustment for Adverse Reactions

Myelosuppression
  • In clinical studies, myelosuppression was managed by dose interruption, dose reduction, or discontinuation of study therapy. Hematopoietic growth factor has been used in patients with resistant myelosuppression. Guidelines for dose modifications are summarized in Table 1.

(revision of the Adverse Reactions section of the package insert to include discontinuation rate due to myelosuppression to 5%)

-
-